Early cellular plasticity promotes progression and dissemination in pancreatic adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic success and a persistently low 5-year survival rate. Despite significant advances in genomics and tumor biology, a fundamental challenge persists: to identify the elusive transformation from common benign pancreatic lesions to occasional malignant cellular identity. This review addresses a critical missing link in PDAC pathogenesis, focusing on when and where the switch to malignancy occurs, and why surgical intervention is often insufficient. We explore the biological and spatial-temporal evolution of precancerous lesions, such as PanINs and IPMNs, and examine how phenotypic plasticity and overlapping cellular programs-including squamous transdifferentiation, epithelial-to-mesenchymal transition (EMT), and acquisition of mesenchymal features-contribute to early dissemination, treatment resistance, and surgical failure. Recognizing and characterizing these early molecular events is essential for rethinking therapeutic strategies, identifying actionable biomarkers, and redefining the temporal window when curative intervention is feasible.
Authors
- Thomas M. Wilkie (ORCID: https://orcid.org/0000-0002-9357-637X)
- Giorgio Malpeli (ORCID: https://orcid.org/0000-0002-2996-2903)
- Giulio Innamorati (ORCID: https://orcid.org/0000-0003-0123-8777)
- Luca Giacomello (ORCID: https://orcid.org/0000-0002-5170-9584)
- Roberto Salvia
Institutions
- University of Verona (IT)
- Link Campus University (IT)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Cancer and Metastasis Reviews
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s10555-026-10326-1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Associazione Italiana per la Ricerca sul Cancro
- Università degli Studi di Verona
- National Cancer Institute